Sutro Biopharma (STRO) Operating Income (2017 - 2025)

Sutro Biopharma has disclosed Operating Income across 9 years of filings, most recently posting -$38.0 million for Q4 2025.

• Operating Income for Q4 2025 came in at -$38.0 million, up 41.69% year-over-year; the trailing twelve-month figure through Dec 2025 was -$158.4 million (up 33.59% YoY), and the FY2025 annual result was -$158.4 million, up 33.59% from the prior year.
• Operating Income came in at -$38.0 million for Q4 2025 at Sutro Biopharma, up from -$48.5 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of $43.2 million in Q4 2023 to a low of -$68.5 million in Q1 2025.
• The 5-year median for Operating Income is -$40.7 million (2022), against an average of -$35.7 million.
• Across the five-year window, Operating Income soared 187.67% in 2023 and sank 251.23% in 2024, its largest moves.
• Sutro Biopharma's Operating Income stood at -$35.0 million in 2021, then tumbled by 40.49% to -$49.2 million in 2022, then jumped by 187.67% to $43.2 million in 2023, then tumbled by 251.23% to -$65.3 million in 2024, then soared by 41.69% to -$38.0 million in 2025.
• The last three Operating Income figures came in at -$38.0 million (Q4 2025), -$48.5 million (Q3 2025), and -$3.3 million (Q2 2025), per Business Quant data.